The test, BRACAnalysis, assesses a woman’s susceptibility to develop breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes.

The test is done on a blood sample, overnighted to Myriad’s certified laboratory. The two genes are separated from the rest of the DNA and are scanned for abnormalities. The MegaBACE 1000 DNA Analysis System used in the test is a high-throughput, fluorescence-based DNA system utilizing capillary electrophoresis with up to 96 capillaries operating in parallel. The system performs sample injection, gel matrix replacement, DNA separation, detection and data analysis, offering unparalleled fl exibility.

Towards prediction and prevention according to the American Cancer Society, in the USA the average woman has an approximate 10% risk of developing breast cancer over a 70-year life span. However, in women with an abnormal BRCA1 or BRCA2 gene the risk of developing breast cancer by the age of 70 is up to 85%.

The rapid genetic assay enables doctors to help patients determine their susceptibility to breast and ovarian cancer. It helps doctors to make more informed decisions about their options for early cancer detection and risk reduction.

“We are world leaders in cancer predictive medicine,” says Mark H. Skolnick, PhD, Director and Chief Scientific Officer of Myriad Genetics.
“Individuals with a history of cancer in their family use our products to determine their own risk of developing cancer. In the battle against cancer, being forewarned is truly being forearmed. Risk can be managed and cancer may be averted through appropriate precautions.
If the disease is diagnosed early, it may be treated more successfully through a variety of proven options,” Dr Skolnick explains.